Overview

Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of Oral BCD-115 (JSC BIOCAD, Russia) in Combination with Endocrine Therapy in Women with ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
Phase:
Phase 1
Details
Lead Sponsor:
Biocad